Proprietary 3D printing process allows for complex stent geometries and optimized mechanical properties that are difficult to achieve with traditional manufacturing, enabling better biocompatibility and degradation control.
Differentiation
Value Proposition
Provides bioresorbable scaffolds that offer temporary support to blood vessels and then dissolve, reducing long-term risks associated with permanent metal stents.
How They Differentiate
Proprietary multi-nozzle precision 3D printing technology that enables thinner struts and complex geometries compared to traditional laser-cut polymer stents.
Market & Competition
Target Customers
Hospitals, cardiovascular surgeons, and patients with coronary or peripheral artery diseases.
Industry Verticals
["Medical Devices","Healthcare","3D Printing"]
Competitors
Lepu Medical (NeoVas), MicroPort Scientific (Firesorb), Biotronik (Magmaris)
Growth & Milestones
Growth Metrics
Transitioned from R&D to late-stage clinical trials; multiple products granted NMPA 'Green Channel' status.
Major Milestones
["World's first 3D-printed biodegradable vascular stent to enter clinical trials (2019)","Completed Series D funding of over 200 million RMB (2022)","Designated as a National High-Tech Enterprise in China"]
Amatech occupies a distinctive position in the interventional cardiology market by replacing permanent metal stents with bioresorbable scaffolds that provide temporary vessel support and then degrade. This approach addresses the long-term risks of late stent thrombosis and chronic inflammation associated with conventional drug-eluting stents. The company has moved beyond the laser-cutting methods used by most polymer-stent makers, instead developing a proprietary multi-nozzle 3D printing process designed for mass production of bioresorbable vascular stents.
The core product line includes the AMSorb Bioresorbable Coronary Scaffold, bioresorbable peripheral vascular stents, and a 3D printing medical device manufacturing platform. The multi-nozzle process enables thinner struts and complex geometries that are difficult to achieve with traditional manufacturing, improving biocompatibility and allowing precise control over degradation rates. Amatech holds over 50 domestic and international patents related to 3D printing technology and bioresorbable medical materials.
Target customers include hospitals and cardiovascular surgeons treating coronary or peripheral artery diseases. The company has clinical trial collaborations with Fuwai Hospital and Beijing Anzhen Hospital. Amatech's AMSorb scaffold was the world's first 3D-printed biodegradable vascular stent to enter clinical trials in 2019, and multiple products have received NMPA Green Channel status for expedited regulatory review. The company completed a Series D round of over 200 million RMB in 2022, backed by investors including SDIC Venture Capital, China Reform Holdings, and Beijing State-owned Assets Management.
Amatech competes with Lepu Medical's NeoVas, MicroPort Scientific's Firesorb, and Biotronik's Magmaris in the bioresorbable scaffold space. Its differentiation rests on the proprietary multi-nozzle 3D printing technology, which allows for thinner struts and more complex geometries than laser-cut polymer stents. The key open question is whether the company can scale manufacturing to compete with established players on cost and reliability, and whether its clinical data will demonstrate superiority over existing BVS products in long-term outcomes.